IRulya Therapeutics Inc.
Support and Resistance Levels
Past performance
News About IRLA
All events for IRLA
All deals for IRLA
Financial Ratios
Financial Statements
IRLA vs Sector & Peers
About IRulya Therapeutics Inc.
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension. Website quincetx.com
Headquarters South San Francisco, CA, US